| P/E (FY) | — | Sales (TTM) | $525,000 |
| Earnings (TTM) | -$44.8M | ROE | −71.45% |
| Net Margin | −7732.04% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 15.39% |
| Market Cap | $55.9M | Trading Days | 1360 |
| 52W High | 4.10 |
| 52W Low | 0.80 |
| % Off High | −80.05% |
| YTD | −70.89% | 1Y | −78.07% |
| 3Y | −48.88% | 5Y | −85.55% |
| Since incept. (ann.) | −38.36% |
| Ann. Volatility (1Y) | 88.98% | Ann. Volatility (3Y) | 105.71% |
| Sharpe (1Y) | −1.25 | Sharpe (3Y) | 0.32 |
| Max Drawdown (1Y) | −78.07% | Max Drawdown (3Y) | −86.16% |
| Beta (3Y, vs SPY) | 1.92 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SCLX | Scilex Holding Co | $57.9M | — |
| INKT | MiNK Therapeutics, Inc. | $52.5M | — |
| TIL | Instil Bio, Inc. | $49.4M | — |
| ATYR | aTYR PHARMA INC | $48.4M | — |
| LONA | LeonaBio, Inc. | $65.5M | — |
| MGX | Metagenomi Therapeutics, Inc. | $45.6M | — |
| INMB | Inmune Bio, Inc. | $45.5M | — |
| ATRA | Atara Biotherapeutics, Inc. | $70.4M | 3.0 |
| ELUT | ELUTIA INC. | $42.0M | 1.1 |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $76.8M | 16.8 |
| KLRS | Kalaris Therapeutics, Inc. | $79.5M | — |
| DYAI |
| DYADIC INTERNATIONAL INC |
| $38.6M |
| — |
